Skip to content

Study · Not a test of the peptide alone · 2020

1 result

Combined therapy with ligustrazine and paeonol mitigates hepatic fibrosis through destroying mitochondrial integrity of stellate cell.

Kong D, Chen L, Huang W, Zhang Z, Wang L, Zhang F, Zheng S

American journal of translational research15 Apr 2020Cited by 14 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    In hepatic stellate cells, the mitochondrial protective agent SS‑31 partially reversed the inhibition of mitochondrial function caused by ligustrazine and/or paeonol.

    In plain wordsIn cells, SS‑31 partly offset the loss of mitochondrial function caused by two herbal compounds.

    Outcome
    IncreaseHepatic stellate cell mitochondrial function with SS-31 after ligustrazine/paeonol
    Study

    n: not reported in source

    Hepatic stellate cells (HSC)
    Outcome group
    Mitochondrial function · Liver

    Source sentences

    Summary
    The inhibitory effects of ligustrazine or/and Paeonol on mitochondrial function is partially balanced by mitochondrial protective agent SS-31.
    1 context sentence
    Summary · context
    Mito-Tacker fluorescence staining and mitochondrial DNA copy number were measured to observe the effect of ligustrazine or/and paeonol on mitochondrial function of hepatic stellate cell (HSC).

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.